These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37073571)

  • 21. A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
    Sun Y; Fan J; Chen G; Chen X; Du X; Wang Y; Wang H; Sun F; Johnson MG; Bensaci M; Huntington JA; Bruno CJ
    Int J Infect Dis; 2022 Oct; 123():157-165. PubMed ID: 35987467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation.
    Doernberg SB;
    Transpl Infect Dis; 2022 Oct; 24(5):e13888. PubMed ID: 35748640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections.
    Chong YP; Bae IG; Lee SR; Chung JW; Jun JB; Choo EJ; Moon SY; Lee MS; Jeon MH; Song EH; Lee EJ; Park SY; Kim YS
    PLoS One; 2015; 10(4):e0119956. PubMed ID: 25910171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).
    Evans SR; Rubin D; Follmann D; Pennello G; Huskins WC; Powers JH; Schoenfeld D; Chuang-Stein C; Cosgrove SE; Fowler VG; Lautenbach E; Chambers HF
    Clin Infect Dis; 2015 Sep; 61(5):800-6. PubMed ID: 26113652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
    Kong W; Deng T; Li S; Shu Y; Wu Y
    BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C; Solomkin J
    Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint.
    Manning L; Metcalf S; Dymock M; Robinson O; Clark B; Nelson R; Paterson DL; Yates P; Loewenthal M; Dewar D; Huggan P; Davis JS;
    Int J Antimicrob Agents; 2022 Jul; 60(1):106598. PubMed ID: 35533791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
    Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
    Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unlocking the DOOR-how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials.
    Ong SWX; Petersiel N; Loewenthal MR; Daneman N; Tong SYC; Davis JS
    Clin Microbiol Infect; 2023 Aug; 29(8):1024-1030. PubMed ID: 37179006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cool Reception for Desirability of Outcome Ranking (DOOR)/Response Adjusted for Duration of Antibiotic Risk (RADAR) in Intra-abdominal Infections.
    Solomkin JS
    Clin Infect Dis; 2017 Oct; 65(9):1580-1581. PubMed ID: 29020198
    [No Abstract]   [Full Text] [Related]  

  • 32. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eravacycline for the treatment of patients with bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
    Jenkins SG; Fisher AC; Peterson JA; Nicholson SC; Kaniga K
    Curr Med Res Opin; 2009 Dec; 25(12):3029-36. PubMed ID: 19849650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
    J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
    Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
    Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection.
    Barlow A; Heil EL; Claeys KC
    Infect Dis Ther; 2021 Mar; 10(1):605-612. PubMed ID: 33484408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
    Zakrison TL; Hille DA; Namias N
    Surg Infect (Larchmt); 2012 Feb; 13(1):38-42. PubMed ID: 22217196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and internal validation of clinical prediction models for outcomes of complicated intra-abdominal infection.
    Ahmed S; Bonnett L; Melhuish A; Adil MT; Aggarwal I; Ali W; Bennett J; Boldock E; Burns FA; Czarniak E; Dennis R; Flower B; Fok R; Goodman AL; Halai S; Hanna T; Hashem M; Hodgson SH; Hughes G; Hurndall KH; Hyland R; Iqbal MR; Jarchow-MacDonald A; Kailavasan M; Klimovskij M; Laliotis A; Lambourne J; Lawday S; Lee F; Lindsey B; Lund JN; Mabayoje DA; Malik KI; Muir A; Narula HS; Ofor U; Parsons H; Pavelle T; Prescott K; Rajgopal A; Roy I; Sagar J; Scarborough C; Shaikh S; Smart CJ; Snape S; Tabaqchali MA; Tennakoon A; Tilley R; Vink E; White L; Burke D; Kirby A
    Br J Surg; 2021 Apr; 108(4):441-447. PubMed ID: 33615351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.